Company
Aurisco Pharmaceutical Co.,Ltd.
Headquarters: Tiantai, China
Employees: 939
Market Cap
CN¥8.18 Billion
CNY as of Jan. 1, 2025
US$1.12 Billion
Aurisco Pharmaceutical Co.,Ltd. Categories
China Healthcare BiotechnologyChina Healthcare China Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers steroids, oncology, antiretroviral, and other APIs and intermediates. It also provides contract manufacturing services and related development works for chemicals, intermediates, and API's. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥1.43 B |
| EBITDA | CN¥409.9 M |
| Gross Profit TTM | CN¥818.7 M |
| Profit Margin | 23.85% |
| Operating Margin | 32.34% |
| Quarterly Revenue Growth | -3.30% |
Stocks & Indices
Aurisco Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: SSE: 605116 wb_incandescent